After a contentious dispute, Novavax has agreed to refund up to $475 million to the international organization that purchased Covid-19 shots as part of a global vaccination program, but found itself with vaccines that were no longer needed.
The agreement caps a disconcerting episode involving several vaccine makers and Gavi, the Vaccine Alliance, a public-private partnership that worked with the World Health Organization as the Covid-19 pandemic erupted four years ago to bring Covid shots to low- and middle-income countries. But as demand dried up last year, the vaccine makers kept $1.4 billion in prepayments for unused shots.
Gavi found itself in this precarious position due to events surrounding the initial efforts to create the global vaccination program. At the outset, vaccine makers favored supply contracts with wealthy nations that locked in high prices, a step that generated substantial criticism. Meanwhile, the WHO, which launched a vaccination program called COVAX, hoped to vaccinate 70% of the populations in mostly poor countries.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect